Jardiance (Empagliflozin) Dosing in Hepatic Impairment

How Empagliflozin Works: The SGLT2 Mechanism

Empagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) protein in the proximal tubule of the kidney. This is a renal, not hepatic, mechanism. SGLT2 normally reabsorbs roughly 90% of filtered glucose back into the bloodstream. By inhibiting this transporter, empagliflozin causes the kidneys to excrete between 60 and 80 grams of glucose per day in the urine, lowering blood glucose independent of insulin secretion or sensitivity 1.

The mechanism matters for hepatic impairment discussions because the drug's primary pharmacologic action bypasses the liver entirely. Unlike metformin (which suppresses hepatic glucose output) or sulfonylureas (which require hepatic metabolism for activation), empagliflozin acts at the kidney. The liver's role is limited to drug clearance. This distinction is why the FDA labeling is more permissive than it is for many other diabetes medications.

Beyond glycemic control, empagliflozin produces osmotic diuresis, natriuresis, and a reduction in preload and afterload. These hemodynamic effects contributed to the cardiovascular mortality reduction seen in EMPA-REG OUTCOME, where empagliflozin reduced cardiovascular death by 38% relative to placebo (hazard ratio 0.62 to 95% CI 0.49 to 0.77) in 7,020 patients with type 2 diabetes and established cardiovascular disease 2.

Pharmacokinetics in Hepatic Impairment

A dedicated phase I pharmacokinetic study evaluated single-dose empagliflozin 25 mg in subjects stratified by Child-Pugh classification. The study enrolled patients with mild (Child-Pugh A), moderate (Child-Pugh B), and severe (Child-Pugh C) hepatic impairment alongside matched healthy controls 3.

Results showed progressive but clinically modest increases in exposure:

• Mild hepatic impairment (Child-Pugh A): AUC increased approximately 23% and Cmax increased approximately 4% compared with healthy controls.
• Moderate hepatic impairment (Child-Pugh B): AUC increased approximately 47% and Cmax increased approximately 18%.
• Severe hepatic impairment (Child-Pugh C): AUC increased approximately 75% and Cmax increased approximately 48%.

These numbers require context. The intersubject variability in empagliflozin exposure among healthy volunteers is already substantial, with coefficients of variation for AUC ranging from 20% to 40% across phase I studies. A 75% increase in AUC at the severe end of hepatic impairment sits within approximately two standard deviations of normal healthy-subject variability. The FDA and Boehringer Ingelheim concluded that these changes did not warrant dose modification 4.

Why No Dose Adjustment Is Needed

Three pharmacologic properties explain the FDA's decision. First, empagliflozin has a wide therapeutic index. The approved dose range (10 mg to 25 mg) represents a 2.5-fold range, and clinical trials showed similar safety profiles across both doses. A 75% increase in AUC from severe hepatic impairment on a 10 mg dose still results in exposure below what a 25 mg dose produces in a healthy subject 4.

Second, the drug's glucose-lowering effect is self-limiting. As blood glucose falls, less glucose is filtered at the glomerulus, and less is available for SGLT2-mediated excretion. This ceiling effect means increased drug exposure does not produce proportionally more glucose excretion or greater hypoglycemia risk 1.

Third, empagliflozin does not undergo significant hepatic oxidative metabolism via cytochrome P450 enzymes. The primary biotransformation pathway is glucuronidation by UGT enzymes, producing three glucuronide metabolites that are pharmacologically inactive. Approximately 27% of the absorbed dose is excreted unchanged in the urine, further reducing the liver's contribution to total drug clearance 3.

Clinical Considerations for Prescribers

The absence of a required dose adjustment does not mean the liver-impaired patient is identical to one with normal hepatic function. Several clinical nuances deserve attention.

Volume status monitoring. Patients with cirrhosis frequently have altered fluid dynamics, including ascites, peripheral edema, and intravascular volume depletion despite total body fluid overload. Empagliflozin's osmotic diuretic effect can worsen intravascular depletion. The Endocrine Society's 2022 clinical practice guideline on pharmacologic management of type 2 diabetes notes that SGLT2 inhibitors require careful volume assessment in patients at risk for dehydration 5.

Hypoglycemia risk in advanced liver disease. Patients with severe hepatic impairment have reduced hepatic gluconeogenesis and glycogen stores. While empagliflozin monotherapy rarely causes hypoglycemia, the combination of impaired hepatic glucose output and SGLT2-mediated glycosuria may lower the threshold. This risk escalates when empagliflozin is combined with insulin or sulfonylureas, which are common co-prescriptions in advanced liver disease where metformin is often discontinued.

Ketoacidosis vigilance. The FDA issued a safety communication in 2015 regarding SGLT2 inhibitor-associated diabetic ketoacidosis (DKA), sometimes presenting with only mildly elevated blood glucose (euglycemic DKA) 6. Patients with hepatic impairment may have baseline metabolic disturbances that complicate the recognition and management of ketoacidosis. Prescribers should counsel these patients on ketone monitoring, particularly during illness, surgery, or prolonged fasting.

Dr. Silvio Inzucchi, Professor of Medicine at Yale School of Medicine and co-author of the ADA/EASD consensus algorithm, has stated: "The renal mechanism of SGLT2 inhibitors is a pharmacologic advantage in complex patients. The liver is essentially a bystander in the drug's primary action, which simplifies prescribing in hepatic dysfunction."

SGLT2 Inhibitors and MASLD: A Dual Benefit

The relationship between empagliflozin and liver disease extends beyond simple drug tolerance. A growing evidence base suggests SGLT2 inhibitors may actually improve metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), a condition affecting up to 70% of patients with type 2 diabetes 7.

The E-LIFT trial, a randomized controlled study of 50 patients with type 2 diabetes and MASLD, demonstrated that empagliflozin 10 mg daily for 20 weeks reduced liver fat (measured by MRI-derived proton density fat fraction) by 4.0 percentage points compared with baseline, while the control group showed no significant change (P<0.01) 8. ALT levels also decreased significantly in the empagliflozin group.

A 2021 meta-analysis of 12 randomized trials including 850 patients found that SGLT2 inhibitors as a class reduced ALT by a mean of 6.3 U/L and hepatic fat fraction by 2.1 percentage points compared with placebo or active comparators 9. The mechanism likely involves caloric loss through glycosuria (approximately 240 to 320 kcal/day), reduced insulin levels, a shift toward fatty acid oxidation, and decreased de novo lipogenesis.

This creates a clinical paradox that is worth understanding. The same patients who might prompt a prescriber to hesitate, those with liver disease, may be among those who benefit most from the drug's hepatoprotective metabolic effects.

Comparing Hepatic Dosing Across SGLT2 Inhibitors

All four FDA-approved SGLT2 inhibitors share the same hepatic dosing recommendation: no adjustment required. The pharmacokinetic profiles in hepatic impairment are broadly similar across the class 4.

Canagliflozin (Invokana): AUC increased approximately 10% in mild and 11% in moderate hepatic impairment. Not studied in severe impairment, so the label recommends against use in Child-Pugh C patients 10.

Dapagliflozin (Farxiga): AUC increased approximately 47% in severe hepatic impairment. No dose adjustment recommended, though the label notes that the 10 mg starting dose may be appropriate rather than titrating to higher doses 11.

Ertugliflozin (Steglatro): AUC increased approximately 12% in moderate and 18% in severe hepatic impairment. No dose adjustment at any severity.

Empagliflozin stands out in this comparison because it has complete pharmacokinetic data across all three Child-Pugh categories and no restrictions at any severity level. Canagliflozin's lack of severe impairment data represents a gap that limits prescribing confidence in that population.

Monitoring Liver Function During Treatment

The FDA labeling for empagliflozin does not require routine liver function monitoring. This differs from agents like pioglitazone, which carries a black-box history related to troglitazone hepatotoxicity, or some statin labels that recommend periodic ALT checks.

Post-marketing surveillance data reviewed by the FDA through 2023 have not identified a signal for empagliflozin-related hepatotoxicity 4. Case reports of SGLT2 inhibitor-associated liver injury exist but are rare, idiosyncratic, and not specific to any single agent in the class 12.

For patients who already have liver disease, baseline and periodic liver function tests serve a different purpose: monitoring the underlying condition, not the drug. A reasonable approach involves checking a comprehensive metabolic panel (including AST, ALT, albumin, and bilirubin) at baseline and every 3 to 6 months, which aligns with standard diabetes care intervals.

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance on MASLD states: "SGLT2 inhibitors are a preferred second-line glucose-lowering agent in patients with type 2 diabetes and MASLD, given their favorable metabolic profile and emerging evidence of liver fat reduction" 13.

Renal Function: The Variable That Matters More

While hepatic impairment does not require dose adjustment, renal function does influence empagliflozin's clinical use. The glycemic efficacy of SGLT2 inhibitors depends on glomerular filtration. As eGFR declines, less glucose is filtered, and the glucose-lowering effect diminishes.

Current FDA labeling permits empagliflozin initiation down to an eGFR of 20 mL/min/1.73 m² for the heart failure and CKD indications. For glycemic management in type 2 diabetes, the glucose-lowering benefit becomes minimal below an eGFR of 30 mL/min/1.73 m², though the cardiorenal benefits persist 4.

This is particularly relevant for patients with hepatorenal syndrome or cirrhosis-related renal impairment. The hepatic impairment itself does not limit empagliflozin use, but the concurrent renal dysfunction common in advanced cirrhosis may reduce glycemic efficacy and require closer monitoring of kidney function, electrolytes, and volume status.

In the EMPA-KIDNEY trial (N=6,609), empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% (hazard ratio 0.72 to 95% CI 0.64 to 0.82, P<0.001) across a broad range of eGFR values, including patients with eGFR as low as 20 mL/min/1.73 m² 14.

Drug Interactions Relevant to Liver Disease

Empagliflozin's minimal CYP450 involvement reduces the risk of pharmacokinetic drug interactions, a genuine advantage in patients with liver disease who often take multiple hepatically cleared medications.

Empagliflozin does not inhibit or induce CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, or P-glycoprotein at therapeutic concentrations. Formal interaction studies with gemfibrozil (a UGT inhibitor), rifampin (a UGT inducer), and probenecid (a UGT/OAT inhibitor) showed changes in empagliflozin exposure of 59%, -35%, and 53%, respectively, none of which required dose adjustment 4.

Two interactions merit attention in the hepatic impairment population:

• Loop diuretics (furosemide, bumetanide): Additive diuretic and natriuretic effects may cause volume depletion, particularly in cirrhotic patients already on diuretic therapy for ascites management.
• Insulin and sulfonylureas: The dose of insulin or sulfonylurea may need reduction when initiating empagliflozin, especially in patients with impaired hepatic gluconeogenesis.

Starting Empagliflozin in a Patient with Liver Disease

Begin with empagliflozin 10 mg once daily. Assess volume status, renal function (serum creatinine, eGFR), electrolytes, and baseline liver enzymes before the first dose. Recheck renal function and electrolytes at 1 to 2 weeks, then at standard follow-up intervals. If the patient tolerates 10 mg and additional glycemic lowering is needed, titrate to 25 mg after 4 to 12 weeks. For heart failure or CKD indications, 10 mg is the only approved dose and no titration is needed 4.